ATAI - atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
- A drug from atai Life Sciences ( NASDAQ: ATAI ) based on an active component found in the plant kratom led to pain-relieving effects in an early-stage trial .
- The candidate, KUR-101, is an oral form of deuterated mitragynine, the major active alkaloid found in kratom. It is under investigation for opioid use disorder.
- Results showed that KUR-101 was safe and well-tolerated with a dose-proportional pharmacokinetic profile.
- Additional results, including comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, is expected by the end of the year.
- Read why Seeking Alpha contributor Stephen Tobin is bullish on atai Life Sciences ( ATAI ).
For further details see:
atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug